Learn more about a new experimental procedure that uses cancer cells’ DNA repair system against itself to make drug-resistant ...

Cancer cells survive by repairing damage to their DNA—even damage that would normally be fatal. One of their most important ...

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.

Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone Outcomes data for DNA-damaging ...

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous ...

SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous ...

Researchers at AACR described the development of a classifier that identified a proportion of tumor samples with HRD that did not have BRCA1/2 mutations.

I. Platinum-based therapies induce DNA inter-strand crosslinks (ICLs), which exacerbate genomic instability and impede DNA replication. In BRCA1/2-deficient tumor cells, the repair of these DNA ...

A recent study, undertaken by researchers at the Tokyo Metropolitan University and the Tokyo Metropolitan Institute of Medical Science (both Japan), unravels key steps in the process of homologous ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...